108 results
8-K
EX-99.1
ARVN
Arvinas Inc
16 May 24
Regulation FD Disclosure
6:05am
, as a monotherapy and in combination studies; and statements regarding potential therapeutic benefits of vepdegestrant. All statements, other than statements … ), a global collaboration between Pfizer and Arvinas to develop and commercialize vepdegestrant and Pfizer Oncology, including their potential benefits
8-K
ARVN
Arvinas Inc
18 Mar 24
Departure of Directors or Certain Officers
4:45pm
rights, non-disclosure, developments, non-competition and non-solicitation agreement, Dr. Peck will be entitled to the severance benefits provided … under his employment agreement in connection with a termination of his employment without cause or for good reason. These severance benefits include
8-K
EX-99.1
z6hlr5 l9w3d9j5knysn
27 Feb 24
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:02am
8-K
ru31m7gv6 9yv6e
20 Feb 24
Departure of Directors or Certain Officers
4:06pm
S-8
EX-99.4
zflaz6vo
16 Jan 24
Registration of securities for employees
4:03pm
S-3ASR
8cadoq r68to
8 Dec 23
Automatic shelf registration
9:16am
8-K
EX-99.2
4101qlwbcl1 hdl
6 Dec 23
Regulation FD Disclosure
7:01am
8-K
vqnqv6e
6 Dec 23
Regulation FD Disclosure
7:01am
8-K
EX-99.1
6sszc
6 Dec 23
Regulation FD Disclosure
7:01am
8-K
EX-10.2
r4ld isvbhv1bwi
27 Nov 23
Arvinas Announces Oversubscribed $350 Million Private Placement
7:11am
S-3ASR
EX-1.2
6m3n ner3x8g
7 Nov 23
Automatic shelf registration
5:24pm
S-3ASR
vzppy1ryx
7 Nov 23
Automatic shelf registration
5:24pm
S-3ASR
EX-4.4
uetrrjzh8hhsceatdc
7 Nov 23
Automatic shelf registration
5:24pm
S-3ASR
EX-4.5
uoo ve2socekkg36w
7 Nov 23
Automatic shelf registration
5:24pm